(Q33895865)

29 July 2017

0 references

Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia (English)

1 reference

29 July 2017

1 reference

1

1 reference

29 July 2017

C Robertson

2

1 reference

29 July 2017

F Lowe

series ordinal

3

1 reference

29 July 2017

C Roehrborn

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

55

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

533-539

1 reference

Watchful waiting or drug therapy for benign prostatic hyperplasia?

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Vesicourethral healing following radical prostatectomy: is it related to surgical approach?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Novel aromatase and 5 alpha-reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

The value of permixon in benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Meta-analysis of published data using a linear mixed-effects model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900593-2

7 January 2021

10.1016/S0090-4295(99)00593-2

Identifiers

DOI

1 reference

29 July 2017

1 reference